|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An IGF gene expression signature was examined in human breast tumors and cell lines and changes were noted following treatment of cell lines or xenografts with anti-IGF-IR antibodies or tyrosine kinase inhibitors.
|
21177763 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At 73/74 wk, both modes of calorie restriction lowered IGF-I protein expression levels and Akt activation in MTs and mammary fat pads, and CCR increased mTOR, p70S6K, p4EBP1, and HIF-1 expression.
|
21462085 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
|
18316619 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Data from human breast tumors has demonstrated that IGF-IR is over-expressed and hyper-phosphorylated.
|
21882221 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival.
|
17066319 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.
|
17063263 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States.
|
17051426 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women.
|
21562710 |
2011 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
|
17520698 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
|
17520698 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
IGF-1 upregulates electroneutral K-Cl cotransporter KCC3 and KCC4 which are differentially required for breast cancer cell proliferation and invasiveness.
|
17133354 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
|
18596909 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
IGF-I and breast cancer: a meta-analysis.
|
15221971 |
2004 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer.
|
16306136 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.
|
22287600 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, IGF‑1R mRNA expression levels were reversely correlated with miR‑503 expression levels in breast tumors, suggesting that the upregulation of IGF‑1R may be due to downregulation of miR‑503 in breast cancer.
|
28656281 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, inhibitors to the AKT/IGF-1R signaling pathways may provide alternative approaches to block escape pathways and restore hormone sensitivity in resistant breast tumors.
|
25178514 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, we review the rationale for targeting the IGF-1 system in the different BrCa molecular subtypes and in treatment resistant breast tumors with a focus on both the molecular mechanisms and on the clinical perspectives of such approaches in specific population subgroups.
|
29253837 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, a breast tumor-derived signature of high IGF-1 ligand is associated with favorable outcome, in contrast to a previously reported IGF-IR activation signature.
|
22297468 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In general, lesser amounts of IGF-I mRNA were detected in fibroblasts derived from breast tumors or skin.
|
7757999 |
1995 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.
|
17166846 |
2007 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
|
15756256 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
|
17010055 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.
|
18757322 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
|
18045956 |
2007 |